Abstract
The Resistance Landscape of Abivertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, and Clinical Strategy to Overcome Resistance in EGFR T790M-Positive Non-Small Cell Lung Cancer
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have